7 However, the risk of hypoglycemia increases when GLP-1 RAs are administered concomitantly with insulin or insulin secretagogues
[91] In May 2026, the CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorization for the medicinal product Wegovy
This panel benefits individuals taking GLP-1 receptor agonists for diabetes management or weight loss, including those using Ozempic, Wegovy, Mounjaro, or similar medications
What is different from that kind of fluid and regular peripheral edema that people would get from, say, a medication, or because they have a little heart failure or renal failure, their legs swell up, is protein, and that protein is critical
This can make regaining weight after taking GLP-1s seem inevitable
Starting at a higher dose significantly increases the risk of severe side effects, which could compromise the welfare of the subject and the integrity of the study